Table 2 Use of oral antihyperglycemic drugs at pretreatment and discharge
non-Dula (n = 38) | Dula (n = 38) | |||
|---|---|---|---|---|
Pre | Discharge | Pre | Discharge | |
Type of OADs, n (%) | 20 (53) | 25 (66) | 23 (61) | 23 (61) |
DPP-4i, n (%) | 18 (47) | 22 (58) | 20 (53) | 0 (0)***, ### |
BG, n (%) | 4 (11) | 6 (16) | 8 (21) | 9 (24) |
α-GI, n (%) | 2 (5) | 5 (13) | 7 (18) | 11 (29) |
Glinide, n (%) | 0 (0) | 8 (21)** | 2 (5) | 11 (29)** |
SU, n (%) | 2 (5) | 0 (0) | 3 (8) | 1 (3) |
SGLT-2i, n (%) | 0 (0) | 0 (0) | 3 (8) | 2 (5) |
TZD, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |